Polymer Overlap Concentration Determines Minimum Threshold for Stabilizing Amorphous Solid Dispersions

Amorphous solid dispersion formulations represent an increasingly essential formulation strategy for enhancing the aqueous solubility, dissolution rate, and subsequent oral bioavailability of poorly soluble active pharmaceutical ingredients. In a typical binary amorphous solid dispersion, an amorphous drug is molecularly dispersed throughout a polymeric excipient carrier. The polymer component serves several critical functions, including governing drug release kinetics, sustaining drug supersaturation in solution, and preserving physical stability against unwanted crystallization during long-term storage.

The rational design of robust amorphous solid dispersion products requires a comprehensive mechanistic understanding of how polymer excipients inhibit crystallization of the amorphous drug, because crystallization entirely eliminates the solubility advantage offered by the amorphous state. Crystallization fundamentally advances through two distinct kinetic processes: an initial crystal nucleation phase followed by subsequent crystal growth. While the inhibitory effects of polymeric excipients on crystal growth have been studied extensively across pharmaceutical science, the precise influence of polymers on crystal nucleation has remained substantially less understood.

In these metastable systems, the first nucleation time marks the exact duration required for the very first group of critical crystal nuclei to appear within a freshly prepared amorphous solid dispersion. Within polymer physics, the overlap concentration represents the physical boundary above which individual polymer coils begin to contact and touch one another. Below this concentration threshold, polymer coils remain physically isolated from one another within the surrounding amorphous drug matrix.

Experimentally, the value of c* can be determined by locating the distinct slope change on a zero-shear viscosity-composition diagram. When the polymer concentration c remains below c*, the individual polymer coils are isolated, intermolecular interactions between adjacent coils are negligible, and the overall viscosity of the dilute dispersion increases in a linear manner with increasing polymer concentration. When the polymer concentration surpasses c*, however, neighboring polymer coils overlap and entangle with one another. These coil-coil interactions and physical entanglements contribute additionally to the overall viscosity of semidilute or concentrated dispersions, generating a clear crossover from the linear dilute regime to the nonlinear semidilute regime.

Importantly, experimental findings show that the polymer overlap concentration remains largely insensitive to temperature variations and the specific processing methods used to manufacture the dispersion. Whether amorphous solid dispersions are prepared through rapid melt quenching or via spray drying techniques, the crossover concentration c* between the dilute and semidilute regimes remains essentially unchanged.

Systematic evaluations across multiple model systems demonstrated a striking kinetic divergence in crystallization behavior around the overlap threshold. In dispersions where the polymer concentration c is less than or equal to c*, the first nucleation time of the dilute dispersion is essentially identical to that observed for the neat, unformulated amorphous drug. Once the polymer concentration exceeds c*, however, the first nucleation time increases dramatically, substantially delaying the emergence of the first critical crystal nuclei. In sharp contrast, the steady-state rates of crystal nucleation and crystal growth decrease exponentially as polymer concentration rises, showing no abrupt shift or sharp transition near the overlap concentration.

These comparative kinetic observations led researchers to conclude that the polymer overlap concentration c* represents the minimum polymer concentration required to achieve a kinetically stable amorphous solid dispersion product. The effective inhibition of crystallization observed in these amorphous drug-polymer systems is primarily governed by the dramatic delay of the first nucleation event rather than an abrupt alteration in steady-state growth kinetics.

Establishing c* as an accessible and physically meaningful design parameter provides practical guidance for efficient excipient selection and physical stability prediction in high drug-loaded amorphous solid dispersions. Because c* can be experimentally determined using routine rheological measurements and remains robust against thermal and processing histories, it offers substantial utility as an early screening tool during formulation development. Extending this analytical framework across chemically diverse drug-polymer combinations will help formulate generalizable design principles, supporting more efficient development of robust formulations for hard-to-deliver medicines and informing the kinetic stabilization of other metastable pharmaceutical systems.

Subject of Research: Polymer overlap concentration as a physical stability threshold in high drug-loaded amorphous solid dispersions

Article Title: Spotlighting rising researcher Sichen Song: stabilizing high drug loaded amorphous solid dispersions against crystallization

Article References: Song, S. (2026). Spotlighting rising researcher Sichen Song: stabilizing high drug loaded amorphous solid dispersions against crystallization. AAPS Open, 12(1), Article 27. https://doi.org/10.1186/s41120-026-00169-z

Image Credits: AI Generated

DOI: 10.1186/s41120-026-00169-z

Keywords: amorphous solid dispersions, polymer overlap concentration, crystal nucleation, crystal growth, crystallization inhibition, high drug loading, first nucleation time, physical stability, viscosity-composition diagram, zero shear viscosity, semidilute regime, dilute regime, polymeric excipients, spray drying, melt quenching, oral bioavailability, rheological measurements, supersaturation maintenance